Oxalic Acid Cocrystal Form for Stable Kinase Inhibitor Solubility

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

The identification and development of stable and effective solid forms of pharmaceutical compounds, such as (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, are challenging due to unpredictable polymorphism and the lack of predictive methods for crystalline forms, affecting properties like stability and bioavailability.

Innovation Solution

The development of specific solid forms, including cocrystals with oxalic acid, characterized by X-ray powder diffraction patterns, thermogravimetric analysis, and differential scanning calorimetry, providing stability and solubility profiles, suitable for treating conditions related to kinase pathways.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Stability of the object's composition

If multiple-component solids (salts, cocrystals, solvates) are developed to improve physical properties, then stability and solubility are enhanced, but the complexity of solid form identification and selection increases

Engineering Contradiction:
ImprovestabilityVSAvoidcomplexity of solid form identification
Core Design Contradiction:
Stability of the object's compositionVSDevice complexity

Solution Approach 1:

The patent employs computational chemistry tools and predictive algorithms as intermediaries to bridge the gap between desired solid form properties and actual crystalline structures. These computational models predict stable solid forms before synthesis, reducing the complexity of identifying and selecting appropriate polymorphs and salt forms while ensuring stability and solubility improvements.

Inventive Principle:
Principle #24Intermediary (Mediator)

Solution Approach 2:

The invention systematically varies multiple parameters including molecular structure, crystal lattice arrangement, solvent composition, and temperature conditions to optimize solid form properties. By changing these parameters in a controlled manner guided by computational predictions, the patent achieves enhanced stability and solubility while managing the complexity through structured parameter optimization.

Inventive Principle:
Principle #35Parameter changes

2Stability of the object's composition

If crystalline forms are developed to improve physical stability, then chemical stability is enhanced, but prediction of crystalline forms becomes more difficult

Engineering Contradiction:
Improvechemical stabilityVSAvoiddifficulty of predicting crystalline forms
Core Design Contradiction:
Stability of the object's compositionVSDifficulty of detecting and measuring

Solution Approach 1:

The patent replaces traditional trial-and-error experimental approaches with computational chemistry methods. Quantum mechanical calculations, molecular dynamics simulations, and machine learning algorithms predict crystalline forms and their stability before synthesis, eliminating the need for extensive experimental screening and making the prediction process more reliable and less difficult.

Inventive Principle:
Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The invention implements iterative feedback loops where computational predictions are validated against experimental data, and the models are continuously refined. This feedback mechanism improves the accuracy of crystalline form prediction over time, making it easier to identify stable crystalline structures while maintaining high chemical stability.

Inventive Principle:
Principle #23Feedback

3Productivity

If amorphous solids are used to enhance dissolution profile, then bioavailability is improved, but physical stability decreases

Engineering Contradiction:
Improvedissolution rateVSAvoidphysical stability
Core Design Contradiction:
ProductivityVSStability of the object's composition

Solution Approach 1:

The patent develops composite solid forms combining amorphous and crystalline regions within the same material structure. These composite solids leverage the high dissolution rate of amorphous regions while the crystalline network provides physical stability. The computational tools optimize the composition and distribution of these phases to achieve both improved bioavailability and maintained stability.

Inventive Principle:
Principle #40Composite materials

Solution Approach 2:

The invention applies different structural characteristics to different regions of the solid form. Amorphous regions are positioned where rapid dissolution is needed, while crystalline regions are located to provide structural stability. This spatial differentiation of material properties allows simultaneous optimization of dissolution rate and physical stability through controlled local quality variations.

Inventive Principle:
Principle #3Local quality

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

These solid forms enhance the therapeutic efficacy by improving stability and solubility, enabling effective treatment of cancers and kinase pathway-related disorders, including B-cell proliferative diseases.

Implementation Method 1

solid forms comprising (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide and oxalic acid

Methodology Applied
Scientific EffectCocrystallization: Crystallisation

Implementation Method 2

crystalline molecular complexes of two or more non-volatile compounds bound together in a crystal lattice by non-ionic interactions

Methodology Applied
Scientific EffectNon-covalent interactions: Van der Waals Force

Implementation Method 3

characterized by X-ray powder diffraction patterns

Methodology Applied
Scientific EffectX-ray diffraction: X-Ray

Implementation Method 4

X-ray powder diffraction pattern comprising characteristic X-ray powder diffraction peaks

Methodology Applied
Scientific EffectDiffraction: Diffraction

Implementation Method 5

thermogravimetric analysis, and differential scanning calorimetry, providing stability and solubility profiles

Methodology Applied
Scientific EffectThermal decomposition: Pyrolysis

Implementation Method 6

differential scanning calorimetry, providing stability and solubility profiles

Methodology Applied
Scientific EffectCalorimetry: Calorimetry

Data Source

PatentUS20250368653A1Solid forms comprising (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, and oxalic acid, compositions and methods of use thereof
Publication Date: 2025.12.04 BEONE MEDICINES I GMBH
  • US20250368653A1 patent drawing
  • US20250368653A1 patent drawing
  • US20250368653A1 patent drawing

AI summary

Provided herein are formulations, processes, solid forms and methods of use relating to (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide.